Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLFS NASDAQ:DCTH NYSE:ENOV NASDAQ:EYE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLFSBioLife Solutions$26.69+2.3%$22.91$17.86▼$29.62$1.28B2792,914 shs829,403 shsDCTHDelcath Systems$11.79+0.6%$10.86$8.12▼$15.57$404.59M0.54517,598 shs448,299 shsENOVEnovis$20.91-4.1%$24.00$20.55▼$36.82$1.25B1.381.03 million shs845,447 shsEYENational Vision$17.96-3.5%$20.70$14.75▼$30.02$1.49B1.082.24 million shs2.22 million shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLFSBioLife Solutions0.00%-2.06%+25.72%+36.79%+18.47%DCTHDelcath Systems0.00%+9.84%+5.87%+19.47%-23.60%ENOVEnovis0.00%-8.64%-10.78%-6.58%-31.90%EYENational Vision0.00%+20.53%+6.65%-30.97%-13.48%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLFSBioLife Solutions$26.69+2.3%$22.91$17.86▼$29.62$1.28B2792,914 shs829,403 shsDCTHDelcath Systems$11.79+0.6%$10.86$8.12▼$15.57$404.59M0.54517,598 shs448,299 shsENOVEnovis$20.91-4.1%$24.00$20.55▼$36.82$1.25B1.381.03 million shs845,447 shsEYENational Vision$17.96-3.5%$20.70$14.75▼$30.02$1.49B1.082.24 million shs2.22 million shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLFSBioLife Solutions0.00%-2.06%+25.72%+36.79%+18.47%DCTHDelcath Systems0.00%+9.84%+5.87%+19.47%-23.60%ENOVEnovis0.00%-8.64%-10.78%-6.58%-31.90%EYENational Vision0.00%+20.53%+6.65%-30.97%-13.48%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLFSBioLife Solutions 2.40Hold$32.0019.90% UpsideDCTHDelcath Systems 2.43Hold$22.5090.84% UpsideENOVEnovis 2.67Moderate Buy$44.50112.82% UpsideEYENational Vision 2.58Moderate Buy$30.0867.50% UpsideCurrent Analyst Ratings BreakdownLatest DCTH, ENOV, EYE, and BLFS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/1/2026ENOVEnovis Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/22/2026ENOVEnovis BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$39.005/15/2026EYENational Vision CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$40.00 ➝ $39.005/14/2026EYENational Vision Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C-) ➝ Hold (C)5/14/2026EYENational Vision Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$25.005/14/2026EYENational Vision UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$42.00 ➝ $36.005/14/2026EYENational Vision Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$30.00 ➝ $22.005/14/2026EYENational Vision BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$38.00 ➝ $27.005/14/2026EYENational Vision Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$30.00 ➝ $20.005/14/2026EYENational Vision Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$35.00 ➝ $30.005/12/2026BLFSBioLife Solutions Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 6/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLFSBioLife Solutions$96.21M13.55$0.23 per share113.98$7.72 per share3.46DCTHDelcath Systems$85.23M4.78$0.05 per share224.20$3.15 per share3.74ENOVEnovis$2.25B0.54$25.81 per share0.81$26.09 per share0.80EYENational Vision$1.99B0.72$1.73 per share10.40$10.96 per share1.64Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLFSBioLife Solutions-$4.59M-$0.08217.50133.45N/A-2.80%1.81%1.65%8/6/2026 (Estimated)DCTHDelcath Systems$2.70M$0.011,172.00N/AN/A0.62%0.51%0.46%8/5/2026 (Estimated)ENOVEnovis-$1.18B-$19.886.455.25N/A-49.92%10.32%4.57%8/6/2026 (Estimated)EYENational Vision$29.60M$0.5727.3722.171.592.31%6.41%2.81%8/5/2026 (Estimated)Latest DCTH, ENOV, EYE, and BLFS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026EYENational Vision$0.43$0.45+$0.02$0.38$545.09 million$543.88 million5/7/2026Q1 2026BLFSBioLife Solutions$0.01$0.04+$0.03$0.02$25.66 million$27.50 million5/7/2026Q1 2026DCTHDelcath Systems-$0.0971-$0.03+$0.0671-$0.03$23.51 million$24.99 million5/7/2026Q1 2026ENOVEnovis$0.82$0.89+$0.07-$0.15$572.02 million$589.15 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBLFSBioLife SolutionsN/AN/AN/AN/AN/ADCTHDelcath SystemsN/AN/AN/AN/AN/AENOVEnovisN/AN/AN/AN/AN/AEYENational VisionN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLFSBioLife SolutionsN/A7.305.50DCTHDelcath SystemsN/A11.2410.33ENOVEnovis0.872.041.05EYENational Vision0.250.620.37Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLFSBioLife Solutions93.24%DCTHDelcath Systems61.12%ENOVEnovis98.45%EYENational VisionN/AInsider OwnershipCompanyInsider OwnershipBLFSBioLife Solutions2.20%DCTHDelcath Systems19.36%ENOVEnovis2.90%EYENational Vision2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLFSBioLife Solutions44048.86 million47.78 millionOptionableDCTHDelcath Systems6034.52 million27.84 millionOptionableENOVEnovis7,80257.56 million55.89 millionOptionableEYENational Vision13,13880.12 million78.19 millionOptionableDCTH, ENOV, EYE, and BLFS HeadlinesRecent News About These CompaniesWhy Is National Vision (EYE) Up 3% Since Last Earnings Report?June 12 at 12:31 PM | zacks.comNational Vision (EYE) Becomes the Sole Eye Care Provider on Every US Army and Air Force BaseJune 4, 2026 | insidermonkey.comNational Vision and Smart Glasses: Early Investing SignalsJune 3, 2026 | zacks.comNational Vision Reaffirms 2026 Outlook, Highlights E-Commerce ProgressJune 3, 2026 | tipranks.comEYE Stock: Valuation, Price Target, and Key Upside DriversJune 2, 2026 | zacks.comJupiter Asset Management Ltd. Grows Stock Holdings in National Vision Holdings, Inc. $EYEMay 29, 2026 | marketbeat.comNational Vision Holdings Inc (EYE) Shares Surge 4.9% -- What GF Score of 74 Tells InvestorsMay 28, 2026 | gurufocus.comWhy National Vision (EYE) is a Top Value Stock for the Long-TermMay 27, 2026 | zacks.comWilliam Blair Investment Management LLC Sells 329,578 Shares of National Vision Holdings, Inc. $EYEMay 24, 2026 | marketbeat.comNational Vision, Inc. Announces Participation in William Blair 46th Annual Growth Stock ConferenceMay 20, 2026 | businesswire.comNational Vision Holdings, Inc. $EYE Shares Sold by Charles Schwab Investment Management Inc.May 17, 2026 | marketbeat.comEYE Q1 Earnings & Revenues Beat Estimates, Operating Margin ExpandsMay 15, 2026 | zacks.comNational Vision Q1 EPS Rises as Revenue Climbs 6.6%, Maintains GuidanceMay 15, 2026 | finance.yahoo.comNational Vision Holdings Inc (EYE) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ...May 14, 2026 | finance.yahoo.comNational Vision shares climb after profit tops expectations despite slight revenue shortfall (EYE)May 13, 2026 | msn.comNational Vision: Q1 Earnings SnapshotMay 13, 2026 | stamfordadvocate.comSNational Vision Holdings, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information about Potentially Recovering Their LossesMay 13, 2026 | globenewswire.comNational Vision Holdings, Inc. (EYE) Q1 2026 Earnings Call TranscriptMay 13, 2026 | seekingalpha.comNational Vision Holdings, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 13, 2026 | seekingalpha.comNational Vision (EYE) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesMay 13, 2026 | zacks.comNational Vision (EYE) Q1 Earnings and Revenues Top EstimatesMay 13, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 20263 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPOBy Ryan Hasson | May 20, 2026AI Server Earnings: Wall Street Sees One Clear StandoutBy Leo Miller | June 5, 2026MarketBeat Week in Review – 05/25 - 05/29By Chris Markoch | May 30, 2026Strategy Inc. Buys Bitcoin and Eyes a Dividend Amid Market FearBy Jeffrey Neal Johnson | May 20, 2026DCTH, ENOV, EYE, and BLFS Company DescriptionsBioLife Solutions NASDAQ:BLFS$26.69 +0.59 (+2.26%) Closing price 04:00 PM EasternExtended Trading$26.89 +0.20 (+0.76%) As of 06:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.Delcath Systems NASDAQ:DCTH$11.79 +0.07 (+0.60%) Closing price 04:00 PM EasternExtended Trading$12.02 +0.23 (+1.96%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.Enovis NYSE:ENOV$20.91 -0.89 (-4.08%) Closing price 03:59 PM EasternExtended Trading$20.98 +0.07 (+0.33%) As of 04:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.National Vision NASDAQ:EYE$17.96 -0.65 (-3.49%) Closing price 04:00 PM EasternExtended Trading$17.95 -0.01 (-0.06%) As of 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.National Vision Holdings, Inc., through its subsidiaries, operates as an optical retailer in the United States. The company operates in two segments, Owned & Host and Legacy. It offers eyeglasses and contact lenses, and optical accessory products; provides eye exams through its America's Best, Eyeglass World, Vista Optical, Fred Meyer, and Vista Optical military, as well as Vision Center branded stores; and offers health maintenance organization and optometric services. National Vision Holdings, Inc. was founded in 1990 and is headquartered in Duluth, Georgia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas What's Behind the Social Media Controversy Surrounding IonQ? Mission Control: Floating In SpaceX's Record-Breaking Orbit 3 Dividend Increases Investors Can Actually Trust RH’s Strong Q1 Still Leaves Investors With One Big Question SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? Alphabet's Most Overlooked Division Just Had a Big Week Robinhood Wants a Bigger Role in IPOs—Here's Why It Matters Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
